tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ANNX Stock Latest News

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Press ReleasesAnnexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
14d ago
ANNX
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
PremiumPress Releases
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
30d ago
ANNX
Annexon reports additional ‘positive’ Phase 3 results for ANX005
PremiumThe Fly
Annexon reports additional ‘positive’ Phase 3 results for ANX005
30d ago
ANNX
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
1M ago
NVD
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
1M ago
ANNX
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
1M ago
DM
FRO
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
1M ago
ACB
GME
Annexon 13M share Secondary priced at $6.25
PremiumThe Fly
Annexon 13M share Secondary priced at $6.25
2M ago
ANNX
Annexon Announces Pricing of $125 Million Underwritten Public Offering
PremiumPress Releases
Annexon Announces Pricing of $125 Million Underwritten Public Offering
2M ago
ANNX
Annexon price target raised to $14 from $10 at Wells Fargo
PremiumThe Fly
Annexon price target raised to $14 from $10 at Wells Fargo
2M ago
ANNX
Annexon Announces Proposed Public Offering of Common Stock
PremiumPress Releases
Annexon Announces Proposed Public Offering of Common Stock
2M ago
ANNX
Annexon offers to sell $125M in common stock
PremiumThe Fly
Annexon offers to sell $125M in common stock
2M ago
ANNX
Annexon price target raised to $12 from $10 at BofA
PremiumThe FlyAnnexon price target raised to $12 from $10 at BofA
2M ago
ANNX
Wells says Annexon should be up more as ANX005 data in line with bull case
PremiumThe Fly
Wells says Annexon should be up more as ANX005 data in line with bull case
2M ago
ANNX
Annexon Biosciences’ ANX005 Shows Promise in GBS Phase 3 Trial
PremiumCompany Announcements
Annexon Biosciences’ ANX005 Shows Promise in GBS Phase 3 Trial
2M ago
8K
ANNX
Annexon announces Phase 3 trial on ANX005 met primary endpoint
PremiumThe Fly
Annexon announces Phase 3 trial on ANX005 met primary endpoint
2M ago
ANNX
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
PremiumPress Releases
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
2M ago
ANNX
Annexon up 48% afterhours at $6.79
PremiumThe Fly
Annexon up 48% afterhours at $6.79
2M ago
ANNX
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
PremiumPress Releases
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
2M ago
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress ReleasesAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2M ago
ANNX
Annexon price target lowered to $10 from $12 at Wells Fargo
PremiumThe Fly
Annexon price target lowered to $10 from $12 at Wells Fargo
2M ago
ANNX
Annexon price target lowered to $11 from $13 at JPMorgan
PremiumThe Fly
Annexon price target lowered to $11 from $13 at JPMorgan
2M ago
ANNX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >